We are building a diversified portfolio of innovative life science companies at various stages of clinical development.
By bringing strategic collaborators and smart investments, we support their drug development efforts through clinical trials to market entry.
Our biotech portfolio companies take advantage of a range of innovative R&D solutions, risk-sharing financing and partnership models, early visibility of study performance through DYNAMIKA platform and tailored strategy for potential pharmaceutical partnerships.
We share R&D risks of clinical development programs and provide in-kind support to biotech and pharma companies, with potential to become a licenced pharmaceutical product, addressing unmet patient needs in immune-oncology, oncology, inflammation, neurology, rare disease, rheumatology, musculoskeletal, immunology markets.
We welcome projects seeking involvement of IAG’ expert team and advisors to bring additional value and increase chances of success for our portfolio companies.
Should a portfolio company aim to seek a non-diluting funds, we are able to provide support including expertise of our academic partners to access national and international funds.
We are interested to discuss
- Development of clinical stage assets
- IP acquisition from the academic partners and biotech companies
- Investment partnerships
- Strategic collaborations
Engage with our team:
Mathematician with 10+ years expertise in actively managing innovation in life science companies, asset positioning, strategy and capital rising. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.
Actively working with biotech companies and investment funds, helping to bridge the gap between academic research, business objectives and finance. Medical computer scientist by background, with strong experience in world-class academic research, biotechnology industry, pharma and equity investment, acquired at leading institutions in the US and Europe. Experienced in identifying life sciences opportunities, establishing their potential value and supporting their development. 10+ years of experience in the strategic use of medical imaging in the assessment of new drug efficacy, trial conceptualizing, design and de-risking.
Results-driven Senior Executive bringing over 16 years of comprehensive achievements in strategic clinical development and operational analysis for biotechnology, pharma and life sciences companies. Recognized for the ability to influence business inflection drivers, develop efficient data strategies and align synergies across multiple stakeholders, which result in increased productivity and value creation. Expertise in creating and maintaining successful strategic partnerships between service providers and sponsors.
‘We understand that developing successful worldwide partnerships is key to supporting patients’ needs. Our team is looking to create win-win situations, bringing the best of science to accelerating novel drug development and commercialization of new therapies. Continuously sharing our expertise and building long-lasting dynamic collaborations is one of the main goal of IAG,’ Dr. Olga Kubassova, CEO.
IAG, Image Analysis Group
IAG’ leading R&D and global operations together with funding mechanisms holistically address the broader issues experienced by biopharma with active and often complex clinical trial pipelines by providing an integrated approach to clinical development and strategic planning.
Partnering Success Stories
Targeted market assessment, patented benchmarking libraries, analytics platform and the most comprehensive expert advisory board help our clients to formulate clear strategy and design the optimal trial for early go / no go decisions.